Abiopharma

🔍 Haddock Jason (Executive)

Company: Merus N.V. (MRUS)

Report Date: 2025-12-12

Detailed Transactions and Holdings:

• Sold 13,193 shares of Share Option (right to buy) at $41.6 per share (Derivative)
  Date: 2025-12-12 | Code: D | Expires: 2035-05-22 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1
• Sold 17,688 shares of Share Option (right to buy) at $48.73 per share (Derivative)
  Date: 2025-12-12 | Code: D | Expires: 2034-05-07 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
• F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.